CN102869663A - 吡唑并吡嗪激酶抑制剂 - Google Patents

吡唑并吡嗪激酶抑制剂 Download PDF

Info

Publication number
CN102869663A
CN102869663A CN2011800104433A CN201180010443A CN102869663A CN 102869663 A CN102869663 A CN 102869663A CN 2011800104433 A CN2011800104433 A CN 2011800104433A CN 201180010443 A CN201180010443 A CN 201180010443A CN 102869663 A CN102869663 A CN 102869663A
Authority
CN
China
Prior art keywords
independently
compound
optional
base
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800104433A
Other languages
English (en)
Chinese (zh)
Inventor
J-M·吉米内斯
L·塞迪默
D·弗雷斯
G·布兰克雷
J·C·戴维斯
A·W·米勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN102869663A publication Critical patent/CN102869663A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2011800104433A 2010-01-27 2011-01-26 吡唑并吡嗪激酶抑制剂 Pending CN102869663A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29866510P 2010-01-27 2010-01-27
US61/298,665 2010-01-27
PCT/US2011/022543 WO2011094288A1 (en) 2010-01-27 2011-01-26 Pyrazolopyrazine kinase inhibitors

Publications (1)

Publication Number Publication Date
CN102869663A true CN102869663A (zh) 2013-01-09

Family

ID=43989802

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800104433A Pending CN102869663A (zh) 2010-01-27 2011-01-26 吡唑并吡嗪激酶抑制剂

Country Status (8)

Country Link
US (1) US8895740B2 (enExample)
EP (1) EP2550272A1 (enExample)
JP (1) JP2013518113A (enExample)
CN (1) CN102869663A (enExample)
AU (1) AU2011209649A1 (enExample)
CA (1) CA2787079A1 (enExample)
MX (1) MX2012008641A (enExample)
WO (1) WO2011094288A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837574A (zh) * 2015-02-02 2016-08-10 四川大学 N-(3-哌啶基)-芳香胺衍生物及其制备方法和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2923765C (en) 2013-09-18 2021-06-29 University Of Canberra Stem cell modulation ii

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024969A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
CN1665809A (zh) * 2001-06-21 2005-09-07 艾文蒂斯药品有限公司 氮杂吲哚
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
US20050288294A1 (en) * 2002-10-30 2005-12-29 Duggan Mark E Inhibitors of akt activity
WO2006058120A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
CN101389626A (zh) * 2004-07-27 2009-03-18 Sgx药物公司 稠环杂环激酶调节剂
WO2010011772A2 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2011008830A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853898A (en) 1971-07-20 1974-12-10 Sandoz Ag 3-(2-substituted amino) pyridyl-phenyl ketone imines
US4988705A (en) 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
FR2601015B1 (fr) 1986-07-04 1988-08-05 Rhone Poulenc Sante Nouveaux derives du 1h,3h-pyrrolo (1,2-c) thiazole, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3827253A1 (de) 1987-08-20 1989-03-02 Sandoz Ag Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US5100768A (en) 1989-05-09 1992-03-31 Kabushiki Kaisha Toshiba Photosensitive composition
JPH03206450A (ja) 1990-01-09 1991-09-09 Fuji Photo Film Co Ltd 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
JPH05331163A (ja) 1991-03-26 1993-12-14 Kumiai Chem Ind Co Ltd ピリジン誘導体及び除草剤
UA44220C2 (uk) 1991-11-07 2002-02-15 Агрево Юк Лімітед Сульфонаміди,що мають гербіцидну активність,спосіб їх одержання, гербіцидна композиція та спосіб боротьби з бур'янами
US5476750A (en) 1992-12-29 1995-12-19 Hoechst Celanese Corporation Metal ion reduction in the raw materials and using a Lewis base to control molecular weight of novolak resin to be used in positive photoresists
DE69404306T2 (de) 1993-05-28 1997-10-30 Pfizer Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
CA2133355A1 (en) 1993-10-04 1995-04-05 Itaru Nitta Method for producing polypeptide
WO1995032963A1 (en) 1994-06-01 1995-12-07 Yoshitomi Pharmaceutical Industries, Ltd. Thienylazole compound and thienotriazolodiazepine compound
WO1996006843A1 (en) 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US5646330A (en) 1995-02-17 1997-07-08 Ciba-Geigy Corporation Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
NZ322197A (en) 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
IL132391A0 (en) 1997-04-18 2001-03-19 Kissei Pharmaceutical Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells
WO1998057957A1 (en) 1997-06-18 1998-12-23 Nissan Chemical Industries, Ltd. Pyridine compounds and herbicides
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
AU2001257490A1 (en) 2000-05-02 2001-11-12 Newbiotics, Inc. Improved beta-lactam antibiotics
AR029289A1 (es) 2000-07-05 2003-06-18 Ishihara Sangyo Kaisha Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
DE10035908A1 (de) 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
NZ525591A (en) 2000-10-05 2004-04-30 Fujisawa Pharmaceutical Co Benzamide compounds as Apo B secretion inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
GB2373245A (en) 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
CN102503903A (zh) 2003-02-07 2012-06-20 詹森药业有限公司 抑制hiv的1,2,4-三嗪
EP1601664B1 (en) 2003-02-28 2008-04-30 Schering Corporation Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders
US20050203067A1 (en) 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
CA2533626A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
EP1689722A2 (en) 2003-10-10 2006-08-16 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
CN101061101B (zh) 2003-12-22 2011-09-07 巴斯利尔药物股份公司 芳酰基呋喃和芳酰基噻吩
ES2364340T3 (es) 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
US7514448B2 (en) 2004-04-02 2009-04-07 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
EP1751119A1 (en) 2004-05-19 2007-02-14 AstraZeneca AB Novel fused heterocycles and uses thereof
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JPWO2006016548A1 (ja) 2004-08-09 2008-05-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗マラリア剤
ATE554087T1 (de) 2004-10-29 2012-05-15 Abbott Lab Neue kinaseinhibitoren
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ES2345997T3 (es) 2005-01-14 2010-10-07 Janssen Pharmaceutica Nv Pirazolopiramidinas como inhibidores de las quinasas del ciclo celular.
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
JP5180816B2 (ja) 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
RU2007141401A (ru) 2005-04-08 2009-05-20 ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) Терапевтический агент для лечения дискинезии
AU2006247322A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
JP4946728B2 (ja) 2007-08-23 2012-06-06 三菱電機株式会社 電力増幅器
WO2009032653A1 (en) * 2007-08-31 2009-03-12 Smith Kline Beecham Corporation Inhibitors of akt activity
US8173635B2 (en) 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665809A (zh) * 2001-06-21 2005-09-07 艾文蒂斯药品有限公司 氮杂吲哚
WO2003024969A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US20050288294A1 (en) * 2002-10-30 2005-12-29 Duggan Mark E Inhibitors of akt activity
WO2005085248A1 (en) * 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
CN101389626A (zh) * 2004-07-27 2009-03-18 Sgx药物公司 稠环杂环激酶调节剂
WO2006058120A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
WO2006058074A1 (en) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
WO2010011772A2 (en) * 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2011008830A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837574A (zh) * 2015-02-02 2016-08-10 四川大学 N-(3-哌啶基)-芳香胺衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US8895740B2 (en) 2014-11-25
MX2012008641A (es) 2012-11-23
JP2013518113A (ja) 2013-05-20
WO2011094288A1 (en) 2011-08-04
AU2011209649A1 (en) 2012-08-09
CA2787079A1 (en) 2011-08-04
US20130053388A1 (en) 2013-02-28
EP2550272A1 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
CN102131807B (zh) 吡唑并吡啶激酶抑制剂
EP2328896B1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
JP5931976B2 (ja) 三環式ピラゾロピリジンキナーゼ阻害剤
JP5542287B2 (ja) ピラゾロピリジンキナーゼ阻害剤
CN102159546A (zh) 氨基吡啶激酶抑制剂
MX2012008642A (es) Inhibidores de cinasas de pirazolopiridinas.
US8895740B2 (en) Pyrazolopyrazine kinase inhibitors
JP2013518114A (ja) ピラゾロピリミジンキナーゼ阻害剤
HK1179267A (en) Pyrazolopyrazine kinase inhibitors
HK1156024A (en) Tri-cyclic pyrazolopyridine kinase inhibitors
HK1156025A (en) Pyrazolopyridine kinase inhibitors
HK1156026B (en) Pyrazolopyridine kinase inhibitors
HK1156617A (en) Tri-cyclic pyrazolopyridine kinase inhibitors
HK1168595A (en) 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179267

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130109